Insulin is considered for the management of T2DM when oral therapies have failed to achieve optimal glycemic control and is considered the initial therapy of choice for patients with a high hemoglobin A1c (≥ 10%) at the time of diagnosis. This evidence concerns the gene INS and type 2 diabetes mellitus.